Oniankitan Owonayo, Ranaivo Nathalie, Carton Laurence, Chevalier Xavier, Claudepierre Pascal
Department of Rheumatology and Spondylis, Henri Mondor Teaching Hospital, Créteil, France.
J Rheumatol. 2005 Jan;32(1):77-9.
To describe in a large population of patients with spondyloarthropathy (SpA) the proportion and characteristics of individuals whose disease was poorly controlled by their current treatment, compared to patients whose disease was well controlled.
We conducted a survey among the members of Spondylis, one of the main not-for-profit SpA patient organizations in France. One thousand anonymous questionnaires were sent to patients throughout France. Among collected data were the opinions of patients about control of their symptoms as well as their past and current treatment.
Five hundred and seven respondents were included in the study of whom 75.9% were receiving nonsteroidal antiinflammatory drugs (NSAID), 55% reported inadequate control, and 45% good control of their nocturnal pain and morning stiffness. The Bath Ankylosing Spondylitis disease activity index (BASDAI) and functional index (BASFI) scores and the rates of occurrence of main symptoms were significantly higher in the group with poorly controlled disease. All drugs except NSAID were more often used currently and in the past by patients with poor disease control.
Conventional treatments failed to provide adequate symptom relief in over half the patients with SpA, despite the use of various drugs in the vast majority of them. Although our results were obtained in a selected patient population, they suggest that a rather large proportion of SpA patients might be candidates for biotherapies.
在大量脊柱关节炎(SpA)患者中,描述当前治疗对疾病控制不佳的个体的比例和特征,并与疾病控制良好的患者进行比较。
我们对法国主要的非营利性SpA患者组织之一Spondylis的成员进行了一项调查。向法国各地的患者发送了1000份匿名问卷。收集的数据包括患者对症状控制的看法以及他们过去和当前的治疗情况。
507名受访者被纳入研究,其中75.9%正在接受非甾体抗炎药(NSAID)治疗,55%报告症状控制不足,45%报告夜间疼痛和晨僵控制良好。疾病控制不佳组的巴斯强直性脊柱炎疾病活动指数(BASDAI)和功能指数(BASFI)评分以及主要症状的发生率显著更高。除NSAID外,目前和过去疾病控制不佳的患者更常使用所有药物。
尽管绝大多数SpA患者使用了各种药物,但传统治疗未能为超过一半的患者提供充分的症状缓解。虽然我们的结果是在特定患者群体中获得的,但它们表明相当大比例的SpA患者可能是生物疗法的候选者。